Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt dahl salt-sensitive rats

Experimental Biology and Medicine

Volumn 231, Issue 6, 2006, Pages 830-833

  Daull, P ^a   Blouin, A ^b   Belleville, K ^b   Beaudoin, M ^b   Arsenault, D ^a   Leonard, H ^b   Sirois, P ^c   Nantel, F ^b   Jeng, A Y ^d   Battistini, B ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b IPS Pharma Inc   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Angiotensin converting enzyme; Endothelin converting enzyme; Neutral endopeptidase 24.11; Vasopeptidase inhibitor CGS 35601

Indexed keywords

CGS 35601; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HEART HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; RAT; SALT INTAKE;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BLOOD PRESSURE; DRUG COMBINATIONS; ENZYME INHIBITORS; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED DAHL; RENIN; SODIUM, DIETARY;

RATTUS NORVEGICUS;

EID: 33744916529     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Manning RD Jr., Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 179:243-250, 2003.
2. Manning RD Jr., Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol 25:311-317, 2005.
3. Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 28:191-202, 2005.
4. Takeda Y. Role of cardiovascular aldosterone in hypertension. Curr Med Chem Cardiovasc Hematol Agents 3:261-266, 2005.
5. Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 47:274-283, 2000.
6. Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45:1145-1152, 2005.
7. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Hori M. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 20:753-761, 2002.
8. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10:83-89, 2004.
9. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051-2059, 2001.
10. Mellin V, Jeng AY, Monteil C, Renet S, Henry JP, Thuillez C, Mulder P. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 46:390-397, 2005.
11. Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 44:S211-S215, 2004.
12. Nantel F, Daull P, Duta DN, Blouin A, Berthiaume N, Cayer J, Beaudoin M, Belleville K, Benrezzak O, Sirois P, Battistini B. Integrated in vivo pharmacology using an instrumented, unrestrained and conscious rat platform: application to rat models of diabetes. J Pharmacol Toxicol Methods. 2005 Nov 6 [Epub ahead of print].
13. Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 18:1606-1613, 2005.
14. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 44:186-190, 2004.
15. Muller DN, Fiebeler A, Park JK, Dechend R, Luft FC. Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage. Clin Nephrol 60(Suppl 1):S2-S12, 2003.
16. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 11:RA155-RA162, 2005.
17. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 23:401-409, 2005.
18. Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 68:456-463, 2005.
19. Elmarakby AA, Morsing P, Pollock JS, Pollock DM. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. Vascul Pharmacol 40:253-259, 2003.
20. Inguimbert N, Poras H, Teffo F, Beslot F, Selkti M, Tomas A, Scalbert E, Bennejean C, Renard P, Fournie-Zaluski MC, Roques BP. N-[2-(Indan-1-yl)-3- mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg Med Chem Lett 12:2001-2005, 2002.
21. Daull P, Blouin A, Beaudoin M, Gadbois S, Belleville K, Cayer J, Berthiaume N, Sirois P, Nantel F, Jeng AY, Battistini B. The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601. Exp Biol Med 231:824-829, 2006.